Shang, Zhiqun <br/><br/>
Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.  [electronic resource] 

 -  Molecular cancer therapeutics  Nov 2015 
 - 2586-94 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-14-1055-T  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Androgen Antagonists--administration & dosage<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>BCG Vaccine--administration & dosage<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Survival--drug effects<br/>Curcumin--administration & dosage<br/>Disease Progression<br/>Drug Synergism<br/>Female<br/>Flutamide--administration & dosage<br/>Gene Expression--drug effects<br/>Humans<br/>Integrin alpha5beta1--genetics<br/>Interleukin-6--genetics<br/>Macrophages--drug effects<br/>Mice<br/>Receptors, Androgen--metabolism<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Treatment Outcome<br/>Urinary Bladder Neoplasms--drug therapy